ALFA Finder| Revenue growth | 6% YoY |
|---|---|
| Margins | EBITDA margin 12.5%; 15.4% excluding one-time API impact. |
| Demand visibility | Strong base business growth across all geographies. |
Growth
Revenue grew 6% YoY but fell 7% QoQ. PAT declined 69% YoY to ₹443 Cr.
Outlook
Focus on peptide/biosimilar growth, resuming semaglutide supplies, and M&A. Net cash surplus remains healthy at ₹3,058 Cr.
Risks
Semaglutide API specification issues, Middle East conflict increasing freight/solvent costs, and US price erosion.
Investor Presentation filed with BSE, NSE: DRREDDY. Summary written with AI assistance from the document.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,386.60
- Market cap
- ₹1,15,736 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 41.3×Sector 43.8×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Dr. Reddy's Laboratories Other Announcement
Dr Reddy's KMP Erez Israeli sold 460,276 ADRs to cover the exercise of 591,270 ADRs allotted under ESOP. The disposal is valued at about ₹61.76 Crore.
- Value
- ₹61.76 Cr
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's allotted 5,91,270 equity shares to employees on exercise of stock options under its ADR ESOP Scheme 2007. Exercise prices ranged from Re.1 to Rs.1,060.20 per share.
Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirms FDA tentative approval for its lenacapavir HIV shot. The company states the news is not material and has no material impact.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth